IL305191A - Methods for treating hereditary chylomicronemia syndrome - Google Patents

Methods for treating hereditary chylomicronemia syndrome

Info

Publication number
IL305191A
IL305191A IL305191A IL30519123A IL305191A IL 305191 A IL305191 A IL 305191A IL 305191 A IL305191 A IL 305191A IL 30519123 A IL30519123 A IL 30519123A IL 305191 A IL305191 A IL 305191A
Authority
IL
Israel
Prior art keywords
patient
lomitapide
dosing period
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
IL305191A
Other languages
English (en)
Hebrew (he)
Original Assignee
Amryt Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amryt Pharmaceuticals Inc filed Critical Amryt Pharmaceuticals Inc
Publication of IL305191A publication Critical patent/IL305191A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4468Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL305191A 2021-03-03 2022-03-03 Methods for treating hereditary chylomicronemia syndrome IL305191A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163155960P 2021-03-03 2021-03-03
US202163165457P 2021-03-24 2021-03-24
PCT/US2022/018672 WO2022187463A1 (en) 2021-03-03 2022-03-03 Methods for treating familial chylomicronemia syndrome

Publications (1)

Publication Number Publication Date
IL305191A true IL305191A (en) 2023-10-01

Family

ID=80819670

Family Applications (1)

Application Number Title Priority Date Filing Date
IL305191A IL305191A (en) 2021-03-03 2022-03-03 Methods for treating hereditary chylomicronemia syndrome

Country Status (10)

Country Link
US (1) US20240165093A1 (https=)
EP (1) EP4301361A1 (https=)
JP (1) JP2024508334A (https=)
KR (1) KR20230153375A (https=)
AU (1) AU2022231007A1 (https=)
BR (1) BR112023016943A2 (https=)
CA (1) CA3208189A1 (https=)
IL (1) IL305191A (https=)
MX (1) MX2023010297A (https=)
WO (1) WO2022187463A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3186856A1 (en) 2020-07-29 2022-02-03 Ruth NALLEN Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595872A (en) 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
US5883109A (en) 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
KR101494067B1 (ko) 2004-03-05 2015-02-16 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 부작용을 최소화하면서 과지질혈증 및 과콜레스테롤혈증과 연관된 질환 또는 질병의 치료 방법
BR102015025502B1 (pt) 2015-04-30 2022-06-21 Aegerion Pharmaceuticals, Inc Composição de lomitapida, tablete, produto de lomitapida, métodos para analisar uma composição de amostra de lomitapida e para determinar uma quantidade de uma impureza em uma amostra da composição

Also Published As

Publication number Publication date
BR112023016943A2 (pt) 2023-10-31
US20240165093A1 (en) 2024-05-23
AU2022231007A9 (en) 2024-09-19
AU2022231007A1 (en) 2023-08-17
KR20230153375A (ko) 2023-11-06
MX2023010297A (es) 2023-09-12
CA3208189A1 (en) 2022-09-09
JP2024508334A (ja) 2024-02-26
EP4301361A1 (en) 2024-01-10
WO2022187463A1 (en) 2022-09-09

Similar Documents

Publication Publication Date Title
IL295459A (en) Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
IL275396B1 (en) Eicosapentaenoic acid and docosapentaenoic acid for use as a medicament for reducing a risk of cardiovascular death
IL274386A (en) Androgen receptor modulator and uses thereof
IL281349B (en) Treatment of diseases related to hepatic stellate cell activity using ammonia-lowering treatments
Perry Lomitapide: a review of its use in adults with homozygous familial hypercholesterolemia
IL309558A (en) Fibrosis treatment
CN105764498A (zh) 纯合家族型高胆固醇血症的治疗
IL284061B2 (en) A preparation containing a relaxant
IL283069B1 (en) Methods of administering corticosteroids
IL258476B (en) Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids
IL297046A (en) Treatment of kidney disease using cer-001
IL279245B2 (en) Compositions comprising menaquinone-7 (mk-7) and/or menquinol for prophylaxis of tissue calcification
IL298145A (en) Combined treatment of liver disorders
IL258224A (en) Compounds for the detection and treatment of growth hormone deficiency
NZ549721A (en) Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
IL305191A (en) Methods for treating hereditary chylomicronemia syndrome
IL305576A (en) Objetive for the treatment of dementia
CA2959488C (en) Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and hmg coa reductase inhibitors
IL298872A (en) Dosage forms of eclobrutinib maleate
IL287131B1 (en) Formulation for oral administration of proteins, peptides and small molecules with low permeability
CN118715010A (zh) 包含二苯基二唑衍生物的药物组合物及其使用方法
IL273988B2 (en) Cannabidiol and chitosan compositions and methods of using the same
IL302718A (en) A tablet for use in the treatment of Huntington's disease and a method for its preparation
RU2857392C2 (ru) Способы лечения синдрома семейной хиломикронемии
IL297114A (en) Compositions comprising 15-hepe for treating or preventing hematologic disorders, and/or related diseases